Hulk Stack
A research blend of CJC-1295 with DAC and Ipamorelin, metered from a single 3 mL pen cartridge, totalling 20 mg.
The Hulk Stack pairs CJC-1295 with DAC and Ipamorelin in a single metered cartridge. Both act on pituitary somatotrophs, but through different receptors — which is the reason they are studied together rather than as duplicates of one another.
The distinction that matters most here is DAC. CJC-1295 exists in two forms: with the drug-affinity complex, and without it (the latter also called Mod GRF 1-29). The DAC conjugate binds serum albumin, and because albumin circulates for a long time, tethering the peptide to it markedly extends how long the compound persists relative to the unconjugated version, which is cleared quickly. The two therefore produce very different exposure profiles and are not substitutes for one another in any study design. This blend uses the with-DAC form; the CJC-1295 entry on this index covers the No-DAC form.
Ipamorelin is a selective pentapeptide agonist at the ghrelin / GH-secretagogue receptor. Published work reports that at concentrations effective for stimulating growth-hormone release in experimental models it does not trigger ACTH or cortisol secretion, unlike earlier growth-hormone-releasing peptides — which is why it is often chosen when the aim is to isolate GH-specific signalling.
Neither component is a licensed medicine in the UK.
Pairs two compounds that act on the same pituitary somatotrophs through different receptors. CJC-1295 is a growth-hormone-releasing hormone (GHRH 1-29) analogue that activates the GHRH receptor; the DAC (drug-affinity complex) conjugate binds serum albumin, markedly extending circulating persistence relative to the unconjugated form. Ipamorelin is a selective pentapeptide agonist at the ghrelin / growth-hormone secretagogue receptor (GHSR-1a). Because the two engage distinct receptors, the pairing is studied for convergent versus independent signalling rather than for an additive effect on one pathway.
- Human evidence
- Individual components studied in preclinical and early clinical research; the combination itself is not the subject of controlled human trials
- Regulatory status
- Neither component is a licensed medicine in the UK. CJC-1295 and Ipamorelin are not approved by the MHRA, FDA or EMA for any indication, and are supplied by research-chemical vendors as laboratory materials rather than as quality-assured pharmaceutical products.
- Comparative study of GHRH-receptor and ghrelin/GHS-receptor signalling within a single experimental system.
- Investigation of receptor cross-talk and dual-pathway regulation in the somatotropic axis.
- Examination of growth-hormone secretagogue activity independent of HPA-axis involvement.
- Analytical studies of peptide stability and compatibility in blended preparations.
- Growth-hormone secretagogues affect the GH/IGF-1 axis; long-term consequences of sustained stimulation are not established in humans.
- The DAC conjugate substantially extends exposure compared with the unconjugated form, so the two CJC-1295 variants are not interchangeable and behave differently in any experimental model.
- Ipamorelin is reported as selective in that, at concentrations effective for GH release in experimental models, it does not trigger ACTH or cortisol secretion — unlike earlier GHRPs such as GHRP-2 and GHRP-6.
- Material sold by research-chemical suppliers is not a pharmaceutical-grade medicine and is not quality-assured for human or veterinary use.
- Components
- CJC-1295 with DAC, Ipamorelin
- Total content
- 20 mg per 3 mL pen cartridge
- Concentration
- 6.67 mg/mL
20 mg across a 3 mL cartridge
- Volume per click
- 0.01 mL
A 3 mL cartridge gives 300 clicks
- Mass per click
- 66.7 mcg
20 mg ÷ 300 clicks — a device specification, not a dose
- CJC-1295 variant
- With DAC (drug-affinity complex)
Distinct from the No-DAC form, also called Mod GRF 1-29 — the two are not interchangeable
Reported research parameters drawn from the cited literature — provided for reference only. These are not dosing, usage, or medical recommendations.
- [1]Ipamorelin, the first selective growth hormone secretagogue (PubMed)pubmed.ncbi.nlm.nih.gov
- [2]PubMed — CJC-1295 and GHRH analogue researchpubmed.ncbi.nlm.nih.gov